4D Molecular Therapeutics, Inc.FDMTNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank13
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-109.08M
↓ 72% vs avg
Percentile
P13
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-63.43M
Historical baseline
PeriodValueYoY Change
2025$-109.08M+18.9%
2024$-134.59M-77.6%
2023$-75.79M+12.6%
2022$-86.69M-25.4%
2021$-69.13M-35.8%
2020$-50.91M-38.7%
2019$-36.71M-125.9%
2018$-16.25M-297.3%
2017$8.24M-